Skip to main content

Diabetes Mellitus: Its Goals Of Therapy!

 GOAL OF THERPY

The goals of treatment of DM includes;

  • Reducing, controlling and managing long-term microvascular, macrovascular and neuropaathic complications.
  • Preserving beta cell function.
  • Preventing acute complications from increased Blood glucosel level.
  • Minimizing hypoglycemic episodes.
  • Maintaining patient quality of life.


--Two landmark trials, THE DIABETES CONTROL AND COMPLICATION TRIAL (DCCT) and THE UNITED KINGDOM PROSPECTIVE DIABETES STUDY(UKPDS), showed that lowering blood glucose levels decreased the risk of developing chronic complications.

--A near normal blood glucose level can be achieved with appropriate patient education, lifestyle modification and medications.

--Proper care of DM requires goal setting and assessment for glycemic control, self-monitoring of blood glucose (SMBG) monitoring of blood glucose pressure, and lipid levels, regular monitoring for the development of complications, dietary and exercise lifestyle modifications and proper medication use 

Proper care of DM requires goal setting and assessment of Glycemic control by; 

  • Monitoring daily blood glucose levels.
  • A1c monitoring 
  • Estimated Average Glucose values (eAG) monitoring.
  • Blood pressure.
  • Lipid levels.


                         1.MONITORING OF BLOOD GLUCOSE LEVELS

                      1. By SMBG.                                                       2. By Glucose sensors.

  • The ADA premeal plasma glucose levels goals are 70-130 mg/dL and peak post-prandial plasma glucose level goals are <180mg/dL. 
  • The American Association of Clinical Endocrinologists (AACE) supports tighter SMBG controls with premeal glucose level goals of < 110mg/dL. and post-prandial glucose level goals of < 140mg/dL.
  • For patients using multiple daily insulin injections or Insulin pumps therapy, the ADA recommends that SMBG be performed at least 3 times daily.

a) SMBG: It is a standard method that enables patient to obtain their current blood glucose levels at any time and is relatively inexpensive.

  • Each patient should be educated regarding how often and when to perform SMBG. 
  •  Typically, in SMBG, a drop of blood is placed on the blood sample size required to as small as 0.3 micrometers, provided the capability of alternate site testing and allowed for the delivery of readings in as few as 5 seconds. 

b) Glucose sensors: Several continuous glucose sensors are now available that works with or independently of insulin pumps. These monitors provide blood glucose readings, primarily through the interstitial fluid (ISF). 

  • A small sterile disposable glucose sensing device called a SENSOR is inserted into the subcutaneous tissues. The sensor then measures the change in glucose in ISF, and sends the information to a monitor, which stores the results.

 2.MONITORING OF HAEMOGLOBIN A1c:

Glucose interacts spontaneously with Hb in RBCs to form glycated derivatives. The most prevalent derivative is A1c because Hb has a life span of approx. 3 months, level of A1c provide a marker reflecting the average glucose levels over this time frame.


  • The ADA goals for persons with DM is less than 7% whereas AACE supports a goal of less than or equal to 6.5% 
  • Testing A1c levels should occur at least twice a year for patients who are meeting treatment goals and 4 times for patients who are not meeting goals 

3.ESTIMATED AVERAGE GLUCOSE eAG:

Estimated Average Glucose is used to correlate A1c values with readings that patients obtain from their home glucose monitors. 
  • The equation to convert from A1c to eAG is.
                                                   eAG(mg/dL) = 28.7*A1c- 46.7 
  • The goal for eAG is 154mg/dL which corresponds with an A1c of less than 7%.
  •  In standardized assay, a 1% rise in A1c translates into 35mg/dL increase in mean glucose.

4.KETONE MONITORING URINE AND BLOOD KETONE TESTING

  • It is important in people with T1DM, in pregnancy with pre-existing diabetes and in GDM. 
  • People with T2DM may have positive ketones and develop into Diabetic ketoacidosis if they are ill.
  • When there is a lack of insulin, peripheral tissues cannot take up and store glucose. this causes the body to think it is starving and because of excessive lipolysis, ketones, primarily Beta-hydroxybutyric acid and aceto-acetic acid, are produced as by-product of free fatty acids metabolism in liver.
  • Glucose and Ketones are osmotically active and when an excessive amount of ketones is formed, the body gets rid of them through urine, leading to dehydration. 
  • Patients with T1DM should test for ketones during acute illness or stress or when blood glucose levels are consistently elevated above 300mg/dL 
  • Women with pre-existing diabetes before pregnancy or with GDM should check ketones using their first morning urine sample or with any symptoms of Diabetic ketoacidosis such as nausea, vomiting or abdominal pain are present
  • Blood ketone testing methods that quantify Beta-hydroxybutyric acid are available and are a preferred way to diagnose and monitor DKA. 

Comments

Popular posts from this blog

Diabetes Mellitus: Clinical Presentation and Diagnosis!

 CLINICAL PRESENTATION AND DIAGNOSIS OF DM 2. SCREENING American Diabetes Association (ADA) recommends routine screening for T2 DM every 3 years in all adults starting at 45 years of age. Testing of T2 DM should be considered in any adult, regardless of their age, who have a BMI greater than or equal to 25kg/m2. The ADA does not currently recommend widespread screening for T1 DM because of the relatively low incidence in the general population, although measurement of Islet antibodies may be appropriate for high-risk individuals. 3.GESTATIONAL DIABETES: "Gestational diabetes is the glucose intolerance in women during pregnancy". All pregnant women who have risk factors for T2 DM should be screened for undiagnosed T2 DM at their first prenatal visit using standard diagnostic criteria.  Any women found to have diabetes in the early point at pregnancy is considered to have T2 DM or GDM. All other pregnant women, not currently known to have DM should be screened for GDM with a 75...

Hospital Acquired Pneumonia- Definition, Predisposing Factors, Clinical Features and Management!

 HOSPITAL ACQUIRED PNEUMONIA Definition: "HAP refers to a new episode of pneumonia occurring at least 2 days after the administration to hospital. It is the most common Hospital Acquired Infection (HAI) and leading cause of HAI-associated death". Predisposing factors: Aspiration of nasopharyngeal secretion Bacteria introduced into the lower GIT. Bacteriaemia Old age Mode of Spread:  Droplet infection Infecting agent: Bacteria: S.pneumonia , S.aureus , H.influenza Virus: Adenovirus, Corona virus, Herpes Simplex Clinical Features: Purulent sputum New radiological infiltrates Temperature > 38 degree Celsius Leukocytosis Investigations: Chest Pain:  to confirm the diagnosis and exclude complication. Pulse Oximetry : to monitor response to oxygen therapy, if SaO2 < 93% features of sever pneumonia, identify ventilatory failure or acidosis. Cell count:  ESR, Neutrophil leukocytosis Microbiological studies:  for severe CAP and those that do not respond to ...

Management of H.pylori and NSAID-associated ulcers Eradication!

MANAGEMENT FOR H.PYLORI ERADICATION It is known that H.pylori infection is associated with over 90% of duodenal ulcers and 80% of Gastric Ulcers. Antibiotics alone or acid-suppressing agents alone, do not eradicate H.pylori . Both therapies act synergistically as growth of the organism occurs at elevated pH and antibiotics efficacy is enhanced during growth. Additionally, increasing intragastric pH may enhance antibiotic absorption. High eradication rates are achieved by a short course of Triple Therapy consisting of:            1 .PPI                                         2. Clarithromycin                         3. Amoxicillin/Metronidazole          in a twice recommended simultaneous regimen. First-Line Therapy :  European Guidelines recommended 1 we...